Cargando…
PSAT189 Severe Hypocalcemia and Hypophosphatemia Associated with Denosumab use in a Chronic Myeloid Leukemia Patient on Imatinib
BACKGROUND: Hypocalcemia and hypophosphatemia are known side effects of Denosumab, especially in presence of risk factors including underlying chronic kidney disease, osteoblastic metastasis, high bone turnover states, vitamin D deficiency and preexisting hypocalcemia. We report a unique case of pro...
Autores principales: | Shah, Tanvi, Panday, Deepika, Alsayed, Mahmoud, Guo, Rong R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624551/ http://dx.doi.org/10.1210/jendso/bvac150.422 |
Ejemplares similares
-
ODP085 Denosumab Induced Severe Hypophosphatemia
por: Del Mar Morales Hernandez, Maria, et al.
Publicado: (2022) -
PSAT209 A Remission of Hypocalcemia in Idiopathic Hypoparathyroidism
por: Puzio, Helene, et al.
Publicado: (2022) -
SAT-347 Diagnosis of Autosomal Dominant Hypocalcemia Type 1 Following the Initiation of Imatinib for Treatment of Chronic Myeloid Leukemia
por: Jones-Ryan, Madeline L, et al.
Publicado: (2020) -
Denosumab Induced Severe Prolonged Hypocalcemia in Metastatic Prostate Cancer
por: Mehmood, Hassan, et al.
Publicado: (2021) -
PSAT210 A Case of Asymptomatic Severe Hypocalcemia: Consideration of Genetic Causes
por: Rosenberg, Rebecca, et al.
Publicado: (2022)